Orgametril, pills 5mg, 30pcs

Composition

Active ingredient:

linestrenol 5 mg;

Auxiliary substances:

potato starch,

alpha-tocopherol,

glycerol,

magnesium stearate,

talc,

lactose monohydrate

Pharmacological action

Orgametril is a progestogen.

Binds to specific cytoplasmic receptors, forming a complex that interacts with the chromatin of target cells.

Causes the transition of the uterine mucosa from the proliferation phase to the secretory phase.

Pharmacodynamics

It has a pronounced atrophic effect on the myometrium; suppresses ovulation and menstruation (with prolonged use in a constant mode).

Indications

• pregnancy prevention infertility
• endometriosis
• miscarriage prevention
• premenstrual syndrome
• menstrual cycle
• disorders uterine bleeding.

Contraindications

• severe liver
• diseases past ectopic pregnancy
• severe diabetes mellitus breast and reproductive system tumors.

Side effects

When using Orgametril as a therapeutic agent, breakthrough bleeding or spotting discharge from the genital tract, increased or decreased libido, nausea, diarrhea, headache, dizziness, weight gain are possible; rarely – nervousness, depression, increased sweating, acne, hirsutism, chloasma, rash, itching, jaundice, changes in liver function tests, decreased glucose tolerance, changes in the lipoprotein spectrum, pain in the mammary glands, increased blood pressure. blood clotting ability.

When using Orgametril as an oral contraceptive, intermenstrual spotting, shortening of the menstrual cycle (less than 25 days) or oligomenorrhea (more than 45 days), nausea, headaches, breast engorgement, weight gain, fluid retention in the body, decreased libido, arterial hypertension, acne, decreased glucose tolerance, pigmentation are possible.

Interaction

Although insufficient data are available, an interaction of Orgametril with other medicinal products is possible. The following interactions have been reported with synthetic progestogens or combined oral contraceptives, and are also related to Orgametril.

Rifamycin, hydantoin derivatives (including phenytoin), barbiturates (including primidone), carbamazepine and aminoglutetimide, laxatives, and activated charcoal may reduce the effectiveness of Orgametril. Conversely, Organometril may increase the therapeutic, pharmacological, or toxicological effects of cyclosporine, theophylline, troleandomycin, and beta-blockers.

Orgamethril may reduce the effectiveness of insulin.

Concomitant use with macrolide antibiotics may increase the risk of developing toxic liver damage.

How to take, course of use and dosage

The drug should be taken orally, washed down with a small amount of water or other liquid. If the next pill is delayed, the woman should take the pill as soon as she remembers, unless the delay in taking it is more than 24 hours.

The first day of the cycle is the first day of menstrual bleeding.

Polymenorrhea: 5 mg (1 tab. )/day from 14 to 25 days of the menstrual cycle.

Menorrhagia and metrorrhagia: 10 mg (2 tablets)/day for 10 days. Usually, the bleeding stops within a few days after starting taking the drug. The course of treatment should be repeated for the next 3 menstrual cycles at 5 mg (1 tab. ) daily from 14 to 25 days of each menstrual cycle. If the therapy performed is ineffective, then additional diagnostic and therapeutic measures should be carried out.

Some cases of primary or secondary amenorrhea or oligomenorrhea: treatment should be initiated with the use of estrogens, for example,20-50 mcg of ethinyl estradiol per day for 25 days. Against the background of taking estrogens, Orgametril is prescribed 5 mg (1 tab. )/day from the 14th to the 25th day of the menstrual cycle. After the end of taking medications, menstrual-like bleeding usually begins after 3 days. Treatment continues (the second cycle), starting from the 5th day, counting from the beginning of spotting: an estrogenic drug is prescribed from the 5th to the 25th day of the menstrual cycle, Orgametril is prescribed from the 14th to the 25th day. The course of treatment should be repeated for at least one more cycle.

Endometriosis: 5-10 mg (1-2 tablets) daily for at least 6 months on a continuous basis.

Some cases of endometrial carcinoma: 30-50 mg (6-10 tablets) per day for long periods.

Benign diseases of the mammary glands: 5 mg (1 tab. ) per day from 14 to 25 days of the menstrual cycle for at least 3-4 months.

To suppress ovulation, ovulatory pain and menstruation; dysmenorrhea: taking the drug Orgametril in a dose of 5 mg (1 tab. ) per day should start from the 1st day of the menstrual cycle, but not later than the 5th day of the menstrual cycle. Treatment can continue for many months (without interruptions). If breakthrough vaginal bleeding occurs during treatment, the dose of the drug can be increased to 10-15 mg (2-3 tablets) per day for 3-5 days.

To delay normal menstruation: taking the drug 5 mg (1 tab. ) per day should be started 2 weeks before the expected start date of menstruation. If treatment is started less than 1 week before the date of menstruation, then the dose of the drug should be increased to 10-15 (2-3 tablets) per day. However, in this case, a delay of more than 1 week is undesirable. The likelihood of breakthrough spotting from the vagina increases with a late start of treatment. For this reason, it is not recommended to start treatment if there are less than 3 days left before the expected menstrual period arrives.

Supplement to estrogen replacement therapy in perimenopause and postmenopause in order to prevent endometrial hyperplasia: Orgametril is prescribed 2.5-5 mg (1/2-1 tab. ) daily for 12-15 days a month (for example, during the first 2 weeks of each month) in this case, estrogen replacement therapy can be carried out continuously at the lowest effective dose.

Overdose

Symptoms: nausea, vomiting.

Treatment: performing symptomatic therapy.

Special instructions

Treatment should be interrupted if the test results indicate impaired liver function.

When taking medications containing estrogen and / or progestogen, especially in women with a history of chloasma in pregnant women, chloasma is sometimes observed. Women who are prone to chloasma should avoid exposing their skin to sunlight or artificial UV radiation.

Taking sex hormones can affect specific laboratory tests. In many patients, during treatment with Orgametril, an increase in blood LDL levels and a decrease in HDL levels may occur. There may be changes in the parameters of liver function, carbohydrate metabolism, and the blood clotting system.

With long-term treatment, systematic medical examinations are indicated; monitoring of lipid and carbohydrate metabolism, bilirubin concentration, transaminases, and the coagulation system. The frequency and nature of systematic medical examinations depend on the circumstances in each individual case and should be determined in accordance with the clinical conclusion, but at least once every 6 months.

Due to the effect of linestrenol on the level of globulin binding sex hormones, Orgametril may show some androgenic activity. This can be expressed in mild signs of virilization (mainly acne or seborrhea).

Epidemiological studies have shown that the use of progestogen in combination with estrogens is associated with an increased incidence of venous thromboembolism (deep vein thrombosis and pulmonary embolism). Despite the fact that the clinical significance of these data for linestrenol without an estrogenic component is unknown. In case of thrombosis, you should stop taking the drug Orgametril. Discontinuation of Orgametril should also be considered in the event of prolonged immobilization due to surgery or disease. Women with a history of thromboembolic diseases should be informed about the possibility of their recurrence.

It is necessary to constantly monitor the condition of patients with circulatory disorders (as well as, if there is a history of them), since the risk of certain cardiovascular diseases or cerebrovascular conditions increases slightly when taking oral estrogen/progestogen contraceptives.

While taking Orgametril, it is recommended to limit the intake of fats and carbohydrates (which is especially important for women with an initially increased body weight).

In patients with diabetes mellitus, the glycemic profile should be monitored (an increase in the dose of insulin may be required).

With a predisposition to arterial hypertension, it is necessary to control blood pressure (reduce fluid intake to 1.5-2 liters/day).

In the case of dysfunctional uterine bleeding in women of reproductive age, it is recommended to start therapy after therapeutic and diagnostic curettage of the uterus.

Ineffectiveness of therapy (relapses of bleeding and endometrial hyperplastic processes) requires clarification of the causes of bleeding.

Ectopic pregnancy should be excluded if menstruation is delayed for a long time during therapy with Orgametril.

Organometril contains lactose as an auxiliary substance in its composition. Therefore, this drug should not be prescribed to patients with rare hereditary problems such as galactose intolerance, lapp lactase deficiency, or glucose-galactose malabsorption.

Influence on the ability to drive motor vehicles and manage mechanisms

Since the drug can cause dizziness, patients should exercise caution when driving vehicles or other equipment.

Composition

Tablet Form of production

Storage conditions

Store in a dry place, protected from light, at a temperature of 2-30 °C

Shelf life

5 years

Active ingredient

Linestrenol

Conditions of release from pharmacies

By prescription

Dosage form

Tablets

Purpose

For women of childbearing age, For women, For adults by doctor’s prescription